Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Receivables - Other: 2018-2025

Historic Receivables - Other for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Mar 2025 value amounting to $108,281.

  • China SXT Pharmaceuticals' Receivables - Other fell 72.24% to $119.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $119.1 billion, marking a year-over-year decrease of 72.24%. This contributed to the annual value of $108,281 for FY2025, which is 29.47% up from last year.
  • According to the latest figures from FY2025, China SXT Pharmaceuticals' Receivables - Other is $108,281, which was up 29.47% from $83,634 recorded in FY2024.
  • Over the past 5 years, China SXT Pharmaceuticals' Receivables - Other peaked at $1.3 million during FY2021, and registered a low of $83,634 during FY2024.
  • Moreover, its 3-year median value for Receivables - Other was $108,281 (2025), whereas its average is $140,852.
  • In the last 5 years, China SXT Pharmaceuticals' Receivables - Other spiked by 64.97% in 2021 and then tumbled by 63.74% in 2024.
  • China SXT Pharmaceuticals' Receivables - Other (Yearly) stood at $1.3 million in 2021, then crashed by 54.58% to $575,773 in 2022, then slumped by 59.94% to $230,642 in 2023, then slumped by 63.74% to $83,634 in 2024, then rose by 29.47% to $108,281 in 2025.